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Abstract

Introduction Multiple studies confirm the occurrence
of ‘white coat adherence’ (WCA), a term describing an
increase in engagement with self-care tasks just prior to a
scheduled clinic appointment, across cohorts with multiple
chronic conditions. In youth with type 1 diabetes (T1D),
research also shows an increase in self-monitoring blood
glucose frequency ahead of youths’ clinic visits. While
studies show preliminary evidence for the occurrence of
WCA in youth with T1D, no study has examined the effect
of WCA and mealtime insulin dosing behaviors in youth
with T1D. The frequency of mealtime insulin bolusing score
(BOLUS) is an objective measure of mealtime insulin use in
youth with T1D that could be vulnerable to WCA. To fill this
gap in the literature and further our understanding of WCA
in pediatric diabetes, we determined whether WCA also
impacts BOLUS scores in youth with T1D.
Research design and methods We extracted insulin
pump records and HbA1c levels from a clinical database
for 459 youth with T1D (Mage=12.5±2.9 years). We
calculated mean BOLUS scores for 6–5, 4–3, and 2–0
weeks prior to youths’ routine clinic visits. We used
multilevel modeling to examine patterns of BOLUS scores
prior to clinic visits and tested for age differences.
Results Multilevel modeling showed a significant increase
in BOLUS scores in the weeks prior to youths’ clinic
appointments (β=0.07, p<0.001). On average, adolescents
had lower BOLUS scores than school-age children
(β=−0.35, p<0.001). Post hoc analyses showed that
adolescents consistently had lower BOLUS scores than
children across assessments (p’s<0.001).
Conclusions Youth with T1D increase their mealtime
insulin use prior to clinic appointments. The BOLUS may be
a viable target for intervention to drive improved glycemic
control. Whether increased tendency to WCA is associated
with reduced risk of diabetic complications remains to be
determined.

Introduction
Many youth with type 1 diabetes (T1D) do
not complete self-management tasks consistently across all days between clinic visits.
‘White coat adherence’ (WCA) is a term that
describes an increase in self-
management
behaviors just prior to a scheduled clinic
appointment.1 Studies show that WCA occurs
in both adult and pediatric populations and
affects a variety of chronic illness groups.2–5

Significance of this study
What is already known about this subject?
►► Research shows evidence for ‘white coat adherence’

(WCA) in youth with type 1 diabetes (T1D) pertaining
to frequency of self-monitoring blood glucose.
►► Specifically, recent studies found youth with T1D
engage in more self-monitoring just before a clinic
appointment.

What are the new findings?
►► Our findings demonstrated that the mealtime insulin

BOLUS score, a validated and objective measure of
insulin use, is also impacted by WCA.
►► BOLUS scores increased significantly in the 6 weeks
leading up to youths’ scheduled clinic appointments,
for both children and adolescents.

How might these results change the focus of
research or clinical practice?
►► Diabetes care teams and researchers should con-

sider using insulin pump downloads from up to 6
weeks prior to clinic appointments to examine more
representative patterns of mealtime insulin use.
►► Our findings highlight the effect of WCA as a potential target for future clinical intervention, in which
youth with T1D may see clinical benefits from more
frequent contact in the period between their clinic
appointments.

In two recent studies, researchers confirmed
the occurrence of WCA in youth with T1D.
Specifically, these studies found that youth
engaged in more frequent blood glucose
monitoring in the weeks just prior to clinic
visits, but there were mixed results for insulin
use.2 6 We previously developed the mealtime
insulin BOLUS score as an objective measure
of mealtime insulin use in youth with T1D
using insulin pump data and confirmed its
validity by associating youth’s BOLUS scores
with current and future glycated hemoglobin (HbA1c) levels.7 8 We also found
BOLUS scores were better able to explain
variability in HbA1c, thus highlighting the
utility of BOLUS scores in describing T1D
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Subjects and methods
We identified eligible youth from the previously described
Mercy on TODP health outcomes database,9 10 which now
contains over 7000 patient records and extracted demographics (ie, child age, race/ethnicity, duration of T1D),
values for HbA1c, and 6 weeks of insulin pump records
from the most recent clinic appointments. Inclusion
criteria for participants in the present study included (1)
child age between 7 and 19 years old, (2) a T1D diagnosis of at least 1 year, (3) daily insulin pump use, and
(4) at least one clinic visit with 6 weeks of insulin pump
data available in the database. These criteria yielded 459
eligible youth.
Data collection
We collected insulin pump data in three 14-day blocks
(6–5, 4–3, and 2–0 weeks) prior to a youth’s routine clinic
visit. We further collected youth’s demographic information as well as HbA1c levels from the corresponding
clinic visit.
Measures
Mealtime insulin BOLUS
The BOLUS provides an objective measure of engagement with mealtime insulin dosing. Specifically, the
BOLUS score is calculated on an integer scale (0–3)
by tallying the presence of at least one carbohydrate-
associated bolus during the time periods 06:00–10:00,
11:00–15:00 and 16:00–22:00 daily. The measure is
reported as a 14-day average of daily scores, with higher
scores indicating more frequent mealtime bolusing.7 We
2

calculated the mean daily BOLUS score for youth within
each of the three monitoring periods (ie, weeks 6–5, 4–3,
and 2–0 before the clinic visit).
Youth HbA1c
Youth’s HbA1c values came from clinical management
using the Tosoh G8 HPLC Analyzer (Tosoh, San Francisco, CA, USA) or the Afinion Point of Care Analyzer
(Abbott Laboratories, Chicago, IL, USA). These are both
reliable methods of measuring HbA1c that are traceable
to Diabetes Control and Complications standards.11 12
Analyses
We used multilevel modeling to examine patterns of
BOLUS scores prior to youth’s clinic visits. We used
multilevel modeling to account for repeated measures
that were nested within a participant and sample sizes
across monitoring periods.13–15 We specified change over
time as a function of time before clinic visit using the
previously described monitoring periods (ie, weeks 6–5,
4–3, and 2–0 before the clinic visit). We centered time
before clinic visit at weeks 6–5 before the clinic visit. We
analyzed age differences in models by using a dichotomous variable for youth age status. For these moderation
analyses, child (<13 years old) was coded as 0 and adolescent (≥13 years old) was coded as 1. We conducted all
analyses using SAS PROC MIXED (SAS V.9.4) and used
the −2 restricted log likelihood (−2LL) to examine the
best fitting model for time. We estimated all models using
the restricted maximum likelihood estimator and used p
values <0.05 to determine statistical significance.
Results
Sample
Youth in our sample had a mean age of 12.5±2.9 years,
a mean duration of T1D of 4.6±3.5 years, and a mean
HbA1c of 8.4%±1.6%. There were 199 adolescents (aged
≥13) and 260 children in our sample and the mean
BOLUS score across monitoring periods was 2.15±0.61.
Trajectory of BOLUS scores
The intraclass correlation for BOLUS scores was 0.763,
suggesting that 76.3% of the variance in BOLUS scores
was between persons. The best fitting model was a
random linear time model; the addition of random linear
time significantly improved model fit, −2ΔLL(∼2)=19.1,
p<0.0001. Overall, we found that time was a significant predictor of BOLUS scores (β=0.054, SE=0.013,
p<0.001), such that BOLUS scores increased in the weeks
leading up to youth’s clinic visits. Figure 1 presents the
change in BOLUS scores across each monitoring period
for the total sample. Next, we examined the effect of
youth age status (ie, child vs adolescent) at baseline and
its interaction with time. Results showed significant main
effects of time (β=0.068, SE=0.018, p<0.001) and age
status (β=−0.35, SE=0.06, p<0.001). However, the interaction of time by age status was not significant (β=−0.032,
SE=0.027, p=0.23), indicating that rate of change for
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self-management behaviors. Whether BOLUS scores are
impacted by WCA remains unknown.
It is important to determine whether WCA impacts
mealtime insulin bolus behaviors because clinicians
typically guide insulin adjustment based on historic self-
management data proximal to a clinic visit (0–2 weeks
prior). Yet, WCA can mask suboptimal self-management
behaviors at times distal to an upcoming clinic visit. If
providers do not witness evidence of suboptimal self-
management, they may fail to offer corrective treatment
guidance or deliver needed behavioral interventions.
Finally, if research demonstrates that WCA influences
HbA1c or average glycemia, then one could hypothesize
that behavioral interventions involving more frequent
contact with the clinician or care team might be more
effective than similar interventions with less frequent
contact.
We sought to determine whether WCA impacts mealtime insulin BOLUS scores in a sample of youth with
T1D. Specifically, we tested the hypothesis that BOLUS
scores would increase just prior to routine clinic visits,
suggesting the occurrence of WCA. We also examined
whether children and adolescents differ in their BOLUS
scores prior to routine clinic visits, which might suggest
differences in WCA effects for the BOLUS as a function
of child age.

Clinical Care/Education/Nutrition

Group
Total sample,
estimate (SE)
Children
Adolescents

Figure 1
sample.

BOLUS scores across monitoring periods for total

BOLUS scores did not differ based on age status. Post
hoc tests showed children had higher BOLUS scores
than adolescents at each monitoring period (6–5 weeks
(β=0.322, SE=0.063, p<0.0001), 4–3 weeks (β=0.406,
SE=0.056, p<0.0001), and 2–0 weeks before clinic visit
(β=0.404, SE=0.055, p<0.0001)). Figure 2 presents the
change in BOLUS across each monitoring period for
children and adolescents. Table 1 presents model estimates for BOLUS scores for the entire sample as well as
subgroups of children and adolescents.
Discussion
This study extends existing research on both WCA and
the BOLUS score in youth with T1D by investigating
the impact of WCA on mealtime insulin BOLUS scores.
In support of our primary hypothesis, our results indicated that youth BOLUS scores appeared to increase
in the weeks prior to routine clinic visits. These findings are consistent with previous studies illustrating
the impact of WCA on frequency of self-monitoring
blood glucose in youth with T1D.2 6 16 When examining

Figure 2 BOLUS scores across monitoring periods for
children versus adolescents.
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BOLUS
score
6–5 weeks

BOLUS
score
4–3 weeks

BOLUS
score
2–0 weeks

2.09 (0.031)

2.14 (0.027)

2.20 (0.029)

2.20 (0.043)
1.88 (0.046)

2.35 (0.037)
1.94 (0.042)

2.36 (0.036)
1.96 (0.042)

developmental differences (ie, children vs adolescents)
on the effect of WCA, we found that adolescents consistently had significantly lower BOLUS scores than children across each time period. Our results showed that
adolescents had BOLUS scores of 0.3–0.4 points lower
than children across each time period; a difference
which translates to nearly five more missed mealtime
boluses for adolescents in each 2 weeks period relative to that for children. However, we did not find an
interaction between time and age status for youth’s
BOLUS scores. That is, overall, children and adolescents both missed an average of 1.5 mealtime boluses
more in weeks 6 and 5 prior to their clinic visit than in
weeks 2 and 1 prior to their clinic visit. In our validation of the BOLUS method, our data suggested that a
1 point increase in youth BOLUS scores may translate
into a 1.5% decrease in youth HbA1c, underscoring
how closely the BOLUS can relate to youth’s glycemic
control.7 Therefore, our current data also suggest
that the seemingly lower BOLUS score in weeks 6 and
5 before youth’s clinic visit may relate to a clinically
significant effect on their HbA1c and overall health.
In the present cohort, youth on average increased
their BOLUS scores as the date of their clinic visit
approached. It is possible that families did this in anticipation of receiving motivation and treatment guidance
from their diabetes care team. However, increasing
mealtime insulin use, even if only for a few weeks, can
help youth to achieve tighter blood glucose levels and
may offer longer term benefits in reducing youth’s
risk of T1D-
related complications.17 18 One could
hypothesize, therefore, that clinicians could leverage
the WCA effect for mealtime insulin use to achieve a
clinical benefit. Namely, youth with T1D may receive
potential value from more frequent clinic appointments or from regular data sharing accompanied by
contact with the youth’s diabetes care team between
clinic visits. Measuring engagement via the BOLUS
score accurately and continuously might also support
improved T1D outcomes by enabling the creation of
‘risk’ alerts to healthcare providers, who could in turn
intensify behavioral treatment approaches to optimize
self-management.
One disadvantage of the WCA effect is that it may give
a false impression of a youth’s average daily level of T1D
self-management if diabetes care teams and researchers
only download and review insulin pump data for the
3
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Table 1 BOLUS scores across assessment points

Clinical Care/Education/Nutrition

4

receiving more intensive experimental interventions
and determine if more frequent contact with diabetes
care teams could help stabilize youth’s mealtime bolus
patterns and help youth to achieve more optimal
glycemic control.
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2 week period immediately before the youth’s clinic
visit. Specifically, 2-week downloads could overestimate
youth’s typical mealtime insulin use and lead diabetes
care teams to make a potentially suboptimal change to
youth’s insulin dosage. Thus, our results also suggest
that diabetes care teams should consider using insulin
pump downloads from up to 6 weeks prior to youth’s
clinic visit to enable them to examine the dynamically
changing pattern of youth’s BOLUS scores and to make
changes in insulin dosages that consider potential WCA
effects.
The strengths of our study include its longitudinal
design, large sample size, and objectively measured
T1D self-
management behavior (ie, BOLUS scores).
However, we also acknowledge several limitations.
One limitation is that our study only examined T1D
engagement for mealtime insulin use in youth using
insulin pumps. We would assert that this is only a minor
limitation because recent data from the T1 Diabetes
Exchange suggest that 63% of youth with T1D in the
USA use an insulin pump.19 Another limitation is that
our study used observational data collected retrospectively from patient records in a research repository; a
prospective data collection would have also allowed
us to perform hypothesis-driven quantitative psychological or behavioral assessments. Therefore, we are
limited in our ability to describe any factors that relate
to our WCA effects and we cannot report on factors that
could have caused the WCA effects. A third limitation
is that our study used clinical data from a Midwestern
single pediatric diabetes center in the USA that serves
patients who are primarily non-
Hispanic White and
middle to upper middle class. Consequently, we must
acknowledge that our results may not generalize to
more diverse racial, ethnic, or socioeconomic samples.
Finally, we acknowledge a fourth limitation related to
our observation period, which we limited to 6 weeks
before a youth’s clinic visit. It is possible that our results
here only reveal part of youth’s pattern of mealtime
insulin use and that future research should consider
calculating youth BOLUS scores continuously between
clinic visits to better track possible WCA effects.
Our study showed WCA effects for youth’s BOLUS
scores in the weeks prior to their routine clinic visits for
T1D regardless of youth age. Because adolescents had
significantly lower BOLUS scores than children across
each time period, our WCA effects may be particularly
clinically noteworthy when caring for adolescents. A
practical implication of our study is the potential value
in measuring youth BOLUS scores for up to 6 weeks
prior to the youth’s clinic visit when interpreting these
data in clinical management or research. Future studies
should assess patterns in WCA for time periods greater
than 6 weeks prior to youth’s routine diabetes clinic
visit and should also consider whether WCA effects
could be further influenced by the time of year (eg,
summer) or sociodemographic factors. Finally, future
clinical trials should examine for WCA effects in youth
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